By Iain Gilbert
Date: Tuesday 26 Aug 2025
(Sharecast News) - Analysts at RBC Capital Markets hiked their target price on gene and cell therapy firm OXB from 800p to 930p on Tuesday following its recent oversubscribed £60m equity funding and revenue guidance reiteration.
By Benjamin Chiou
Date: Friday 15 Aug 2025
(Sharecast News) - Oxford Biomedica has raised £60m via a share placing and subcription to expand its US operations, the gene and cell therapy company announced on Friday.
By Josh White
Date: Friday 01 Aug 2025
(Sharecast News) - Oxford Biomedica announced on Friday that it has agreed a new four-year loan facility of up to $125m with Oaktree Capital Management, refinancing its existing debt and providing additional funding capacity to support future expansion.
Currency | UK Pounds |
Share Price | 566.00p |
Change Today | -5.00p |
% Change | -0.88 % |
52 Week High | 578.00 |
52 Week Low | 232.50 |
Volume | 101,891 |
Shares Issued | 120.17m |
Market Cap | £680.18m |
RiskGrade | 125 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 4 |
Buy | 2 |
Neutral | 4 |
Sell | 0 |
Strong Sell | 0 |
Total | 10 |
No dividends found |
Time | Volume / Share Price |
16:35 | 252 @ 566.00p |
16:35 | 15,574 @ 566.00p |
16:35 | 73 @ 566.00p |
16:35 | 50 @ 566.00p |
16:35 | 46 @ 566.00p |
Chair | Roch Doliveux |
CEO | Frank Mathias |
CFO | Lucinda (Lucy) Crabtree |
You are here: research